BO41843: GDC-9545 WITH PALBOCICLIB OR LETROZOLE WITH PALBOCICLIB IN BREAST CANCER

• Research type

  Research Study

• Full title

  A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

• IRAS ID

  1003435

• Contact name

  Catherine Harper-Wynne

• Contact email

  charperwynne@nhs.net

• Sponsor organisation

  F Hoffmann-La Roche Ltd

• Eudract number

  2020-000119-66

• REC name

  London - Westminster Research Ethics Committee

• REC reference

  20/LO/1114

• Date of REC Opinion

  3 Dec 2020

• REC opinion

  Further Information Favourable Opinion